Funding
Dr. Staff's Translational Neuromuscular Disease Research Laboratory receives a variety of funding for research, including grants from the National Cancer Institute and Regenerative Medicine Minnesota and the Target ALS Foundation.
Here are Dr. Staff's current grants for neurology research:
| Investigator & Role |
Grant Title |
Funding Source |
Duration |
| Nathan P. Staff, M.D., Ph.D., principal investigator |
Assessment of Chemotherapy-Induced Peripheral Neuropathy Susceptibility Using Patient-Derived iPSC Technology (R01 CA 2011887) |
National Cancer Institute |
09/2017-08/2022 |
| Nathan P. Staff, M.D., Ph.D., principal investigator |
Dysregulation of Epidermal MMP-13 as a Cause of Paclitaxel-Induced Peripheral Neuropathy (CA 215973 — Subaward: Sandra Rieger Overall PI) |
National Cancer Institute |
07/2017-06/2019 |
| Nathan P. Staff, M.D., Ph.D., principal investigator |
Intrathecal Mesenchymal Stromal Cell Therapy for ALS: A Phase IIA Study (RMM 11215 CT002) |
Regenerative Medicine Minnesota |
05/2016-04/2019 |
| Nathan P. Staff, M.D., Ph.D., site principal investigator |
Validating Poly(GP) and pNFH as Biomarkers to Detect Symptomatic Conversion in c9ALS (Leonard Petrucelli Overall PI) |
Target ALS Foundation |
05/2017-06/2019 |
| Nathan P. Staff, M.D., Ph.D., principal investigator |
Mechanisms of Bortezomib-Induced Peripheral Neuropathy (K08 CA 169443) |
National Cancer Institute |
07/2012-06/2017 |